

**One-minute summary**

- Evaluation of a real-time RT-PCR assay for the detection of 2019-nCoV. This is a two-step protocol that recommends **screening** using an assay that detects the **E (envelope) gene**, followed by **confirmation** with an assay that detects the **RdRp (RNA-dependent RNA polymerase) gene**.
  - The E gene screening assay detects a broad range of human and bat coronaviruses.
  - The RdRp confirmation assay uses two probes. One probe is **specific for 2019-nCoV and does not cross-react with SARS-CoV, MERS-CoV, or the seasonal human coronaviruses (HKU1, OC43, NL63, 229E)**. The other detects **both 2019-nCoV AND human and bat-related SARS CoVs**, and can be used as a positive control, or omitted.
  - The assay is highly sensitive for 2019-nCoV, with a limit of detection (LOD) of 3.9 copies per reaction and 3.6 copies per reaction for the E gene assay and RdRp gene assay, respectively.
  - The assay is highly specific for 2019-nCoV with no false positive reactions or cross-reactions with other respiratory pathogens.
  - Diagnostic sensitivity and specificity was not determined due to a lack of positive clinical specimens and viral isolates of 2019-nCoV.

**Additional information**

- In addition to the above two targets, an N gene target was also tested but was found to be less analytically sensitive.
- Primer and probe design was based on alignment of 375 sequences of SARS-CoV and 6 sequences of 2019-nCoV.
  - The primers and probe for the E gene assay matches the 2019-nCoV target sequence exactly.
• There is a 1 base pair mismatch in the reverse primer for the RdRp gene assay.

• Validation specimens included: typed coronavirus isolates grown in cell culture, previously tested respiratory patient specimens (including sputum, nose and throat specimens, with and without viral transport media) that were positive for a variety of respiratory pathogens, bat-derived fecal samples containing bat SARS-related coronavirus, and synthetic 2019-nCoV nucleic acid.

• 297 clinical samples containing a variety of respiratory viruses, 13 spiked sputum samples, and water samples were used to determine analytical specificity.
  • No false positives were observed.
  • No cross-reactivity was observed against: seasonal human coronaviruses (HKU1, OC43, NL63, 229E), MERS-CoV, Influenza A (H1N1, N3N2, H5N1, H7N9, untyped), Influenza B (Victoria or Yamagata), Rhinovirus/Enterovirus, Respiratory Syncytial Virus (A/B), Parainfluenza virus (1-4), Adenovirus, human Bocavirus, Legionella spp., and Mycoplasma spp.
Citation

Disclaimer
This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario’s government, public health organizations and health care providers. PHO’s work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

Public Health Ontario
Public Health Ontario is a Crown corporation dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world. For more information about PHO, visit publichealthontario.ca.